{"id":2,"date":"2021-12-02T10:31:48","date_gmt":"2021-12-02T09:31:48","guid":{"rendered":"https:\/\/www.2023roma.org\/?page_id=2"},"modified":"2023-05-18T16:30:18","modified_gmt":"2023-05-18T14:30:18","slug":"scientific-programme","status":"publish","type":"page","link":"https:\/\/www.2023roma.org\/index.php\/scientific-programme\/","title":{"rendered":"Scientific Programme"},"content":{"rendered":"

[vc_row][vc_column][vc_accordion active_tab=”” collapsible=”yes” style=”2″][vc_accordion_tab title=”Day 1″]

<\/div>

Sunday 21 May<\/h2><\/div>
OPENING CEREMONY<\/strong><\/div><\/div>
    \n
  • 17:00-19:00 AUDITORIUM LA NUVOLA – Welcome addresses<\/strong>
    \nPresident of the Congress, S. Bernardini<\/em>
    \nIFCC President, K. Adeli<\/em>
    \nEFLM President, T. Ozben<\/em>
    \nSIBioC President, T. Trenti<\/em>
    \nAnnouncement of IFCC Awards<\/strong>
    \nIFCC President, K. Adeli<\/em>
    \nAnnouncement of EFLM Awards<\/strong>
    \nEFLM President, T. Ozben<\/em>
    \nOpening Lecture<\/strong>
    \nChair: S. Bernardini<\/em>
    \nForgiveness for Individual, Family, and Community Well-Being, R. Enright (USA)<\/em><\/li>\n
  • 20:00 Welcome Cocktail<\/strong><\/li>\n<\/ul>\n<\/div>[\/vc_accordion_tab][vc_accordion_tab title=”Day 2″]
    <\/div>

    Monday 22 May<\/h2><\/div><\/div>
      \n
    • 9:15 – 11:15 ROOM 1 – EFLM SYMPOSIUM<\/span><\/strong>
      \nInappropriate use of laboratory resources \u2013 Demand management tools and how to use them<\/strong> – Session chairs: J. Cadamuro (Austria), M. Salinas (Spain)<\/em>
      \nDefinition and magnitude of over-and underuse – J. Cadamuro (Austria)<\/em>
      \nTools to overcome inappropriate test ordering – A. von Meyer (Germany)<\/em>
      \nDemand management and inappropriate use of laboratory resources – examples of successful interventions – M. Salinas <\/em>(Spain)<\/em>
      \nWeb-based clinical decision support tools to guide appropriate use of laboratory testing – R. Liwayan (Australia)<\/em>
      \nThe impact of Computer-assisted automatic algorithms in the diagnosis of anemia in Primary Care – E. Urrechaga (Spain)<\/em>
      \nCredits: 2 CPECS\u00ae<\/strong><\/span><\/li>\n
    • 9:15- 11:15 AUDITORIUM LA NUVOLA – IFCC SYMPOSIUM<\/span><\/strong>
      \nArtificial intelligence applications in clinical laboratory medicine<\/strong> – Session chairs:\u00a0A. Carobene (Italy),<\/em> D. Gruson (Belgium)<\/em>
      \nArtificial intelligence: current and future applications in laboratory medicine \u2013 D. Gruson (Belgium)<\/em>
      \nThe Ethics of Point of Care Devices and the Need for AI Policy Frameworks in Resources Limited Settings \u2013 M. Gmira (Morocco)<\/em>
      \nThe value of AI in the mobile health ecosystem \u2013 N. Delvaux (Belgium)<\/em>
      \nComplete Blood Count based Machine Learning Algorithms for Sepsis Detection – L. Agnello (Italy)<\/em>
      \nArtificial Intelligence Applied To The Prevention Of Non-Alcoholic Steatohepatitis In Primary Care Using Fib-4 As A Fibrosis Marker – S. S\u00e1nchez Berdial (Spain)<\/em>
      \nCredits: 2 CPECS\u00ae<\/strong><\/span><\/li>\n
    • 9:15 – 11:15 ROOM 3 – IFCC SYMPOSIUM<\/span><\/strong>
      \nPrecision Medicine will boost Medical Test Standardization of Protein Biomarkers<\/strong> – Session chairs: C. Cobbaert (Netherlands), P. Gillery (France)<\/em>
      \nCritical Appraisal of IFCC SD standardization\/harmonization efforts: making up the balance – P. Gillery (France)<\/em>
      \nEmbracing (patho-)physiological diversity at the molecular level: unraveling the human blood proteome – N. Kelleher (USA)<\/em>
      \nPromising (glyco-)proteoform measuring technologies to accurately quantify the measurand of interest: what is in the pipeline? – Y. van der Burgt (Netherlands)<\/em>
      \nBottom-up proteomics enables peptide-based calibration of molecular defined proteins for realizing SI-traceability of test results – C. Cobbaert (Netherlands)<\/em>
      \nCredits: 2 CPECS\u00ae<\/strong><\/span><\/li>\n
    • 9:15 – 11:15 ROOM 2 –\u00a0SYMPOSIUM 1<\/strong>
      \nMicroRNA: from detection technologies to applications<\/strong> – Session chairs:\u00a0P. Ahmad-Nejad (Germany),<\/em> V. Taly (France)<\/em>
      \nEV associated Biomarkers in Liquid Biopsies – How to identify valid microRNA Biomarker Signatures in circulating extracellular vesicles – M. W. Pfaffl (Germany)<\/em>
      \nDroplet-based microfluidics for miRNA detection – V. Taly (France)<\/em>
      \nmiRNA profiling in cells and extra-cellular vesicles using high-throughput sequencing in human diseases and disease models – J. Tost (France)<\/em>
      \nThe effect of resveratrol on hyperglycemia-related microRNAs in HepG2 cells – A.M. Tshivhase (South Africa)<\/em>
      \nMaternal MT2A gene polymorphisms \u20135A\/G, \u2013209A\/G and +838G\/C influence trace element levels in healthy postpartum women and their offspring – D. Pa\u0161ali\u0107 (Croatia)<\/em>
      \nCredits: 2 CPECS\u00ae<\/strong><\/span><\/li>\n
    • 9:15 – 11.15 ROOM 4 – EFLM SYMPOSIUM<\/span><\/strong>
      \nPrecision Medicine<\/strong> – Session chairs:\u00a0R. Abu Seir (USA),<\/em> T. Ozben (Turkey)<\/em>
      \nMulti-omics profiling in the era of cancer Precision Medicine \u2013 T. Ozben (Turkey)<\/em>
      \nGenetic diagnosis and multi-omics clustering for diabetes precision medicine \u2013 P. Froguel (UK)<\/em>
      \nComputer-assisted integration of multi-dimensional patient\u2019s data for poly-therapies management \u2013 M. Simmaco (Italy)<\/em>
      \nIntegration of germline and tumour genetics into a pathology supported genetic testing algorithm for improved risk management of breast cancer in South Africa – L. Mampunye (South Africa)<\/em>
      \nSwiss BioRef: A national infrastructure for generating precise reference intervals for diagnostic medicine –T.E. Blatter (Switzerland)<\/em>
      \nCredits: 2 CPECS\u00ae<\/strong><\/span><\/li>\n
    • 9:15 – 11:15 ROOM 5 – SIBioC SYMPOSIUM<\/span><\/strong>
      \nOpportunities and challenges for digital morphology in Hematology<\/strong> – Session Chairs: S. Buoro (Italy), G. Da Rin (Italy)<\/em>
      \nFrom the digital microscope to artificial intelligence – G. D\u2019Onofrio (Italy)<\/em>
      \nThe virtual slide in hematology – G. Zini (Italy)<\/em>
      \nDigital morphology analyzers in hematology: a disruptive innovation? The experience of SIBioC hematology study group – M. Seghezzi (Italy)<\/em>
      \nNED-DH: a new interesting tool for digital morphology –\u00a0J. Sabbatinelli (Italy)<\/em>
      \nFlagging performance of Alinity hq and Sysmex XN1000 for atypical lymphocites – O.R. Oprea (Romania)<\/em>
      \nCredits: 2 CPECS\u00ae<\/strong><\/span><\/li>\n
    • 11:45 – 12:45 AUDITORIUM LA NUVOLA –\u00a0\u00a0PLENARY LECTURE – <\/strong>Chair: K. Adeli (Canada)
      \n<\/em>Cancer metabolism – G. Melino (Italy)<\/em>
      \nCredit: 1 CPECS\u00ae<\/strong><\/span><\/li>\n
    • 14:30 – 16:30 AUDITORIUM LA NUVOLA – IFCC SYMPOSIUM<\/span><\/strong>
      \nCentral Role of the Clinical Laboratory in Public Health & Patient Care Continuum<\/strong> – Session chairs: R. Erasmus (South Africa), A. St John (Australia)<\/em>
      \nCritical review of the evidence supporting the value of laboratory medicine in clinical care – K. Adeli (Canada)<\/em>
      \nDelivering value through improved test implementation – A. St John (Australia)<\/em>
      \nDemonstrating the value of laboratory medicine from an industry perspective – B. Meyer (UK)<\/em>
      \nStrategies for Promoting the Value of Laboratory Medicine in North America – D. Kinniburgh (Canada)<\/em>
      \nCredits: 2 CPECS\u00ae<\/strong><\/span><\/li>\n
    • 14:30 – 15:30 ROOM 6 – MEET THE EXPERT<\/strong>
      \nInfrared spectroscopy – S. De Bruyne (Belgium)<\/em>
      \nCredits: 1 CPECS\u00ae<\/strong><\/span><\/li>\n
    • 15:45 – 16:45 ROOM 6 – DEBATE<\/strong>
      \nCardiac Biomarkers in Risk Stratification: Laboratory Medicine Approach – F. Apple (USA)
      \nCardiac biomarkers in risk stratification: the need for more data – N. Mills (UK)<\/em>
      \nCredits: 1 CPECS\u00ae<\/strong><\/span><\/li>\n
    • 16:30-18:00 AUDITORIUM LA NUVOLA – ROUND TABLE<\/span>
      \nMachine Learning in Laboratory Medicine: Recommendations from the IFCC Working Group & Case Studies<\/strong> \u2013 Chair N. Rifai (USA)<\/em>
      \nSpeakers: S. Master (USA), T. Badrick (Australia), S. Haymond (USA), A. Bietenbeck (Germany)<\/em>
      \nCredits: 1,5 CPECS\u00ae<\/strong><\/span><\/li>\n<\/ul>\n<\/div>[\/vc_accordion_tab][vc_accordion_tab title=”Day 3″]
      <\/div>

      Tuesday 23 May<\/h2><\/div><\/div>
        \n
      • 9:15 – 11:15 ROOM 1 – SYMPOSIUM 2<\/strong>
        \nCOVID-19 diagnosis, therapy and outcome<\/strong> – Session chair: M. Ciccozzi (Italy), G. Lippi (Italy)<\/em>
        \nSARS-CoV-2: Epidemiological and genomic analysis \u2013 L.B. Snell (UK)<\/em>
        \nChallenges in COVID-19 testing strategies \u2013 P. M Bossuyt (Netherlands)<\/em>
        \nSevere COVID-19: is it a viral or an immunological disease? – A. Guillon (France)<\/em>
        \nEvaluating SARS-CoV-2 Antibody Reactivity to Natural Exposure and Inactivated Vaccination with Peptide Microarrays –
        \nP. Zheng (China)<\/em>
        \nCirculating Histones Induce Platelet Aggregation And Trigger Inflammatory Responses – L. Agnello (Italy)<\/em>
        \nCredits: 2 CPECS\u00ae<\/strong><\/span><\/li>\n
      • 9:15 – 11:15 ROOM 2 – SYMPOSIUM 3<\/strong>
        \nDiagnostic Challenges in Sepsis<\/strong> – Session chairs:\u00a0B. Gouget (France),<\/em> C. Tsatsanis (Greece)<\/em>
        \nImmunology of sepsis: diagnostic and therapeutic challenges\u2013 T. Van der Poll (Netherlands)<\/em>
        \nHarmonisation of Procalcitonin as a sepsis biomarker: problems and solutions \u2013 V. Delatour (France)<\/em>
        \nFunctional biomarkers of Sepsis Immunosuppression – C. Tsatsanis (Greece)<\/em>
        \nThe Utility Of The Mindray BC 6800 Plus Analyzer\u2019s Parameters For Detecting Sepsis – S. Sacchetti (Italy)<\/em>
        \nAccessing the role of the 16SrRNA gene in the early diagnosis of neonatal sepsis in a Tertiary care Hospital –A. Prashant (India)<\/em>
        \nCredits: 2 CPECS\u00ae<\/strong><\/span><\/li>\n
      • 9:15 – 11:15 ROOM 3 – SYMPOSIUM 4<\/strong>
        \nTowards the next generation of Laboratory Information Systems<\/strong> – Session chairs:\u00a0V. Luki\u0107 (Serbia), M. Yusof (Malaysia)<\/em>
        \nLIS 2.0: what does the future hold? – V. Luki\u0107 (Serbia)<\/em>
        \nAre laboratory information systems prepared for interconnected health care? \u2013 A. Bietenbeck (Germany)<\/em>
        \nAn evaluation framework for effective and safe laboratory information systems \u2013 M. Yusof (Malaysia)<\/em>
        \nHaving the future in mind when thinking at Laboratory Information Management Systems – M.A. Fitarau (Romania)<\/em>
        \nDirect integration between LIS and EQA provider portal supports faster and more consistent result reporting – K. Virtanen (Finland)<\/em>
        \nCredits: 2 CPECS\u00ae<\/strong><\/span><\/li>\n
      • 9.15 – 11.15 ROOM 4 – SYMPOSIUM 5 <\/strong>
        \nAutoimmune diseases<\/strong> – Session chairs: D. Barnali (India), J. Sheldon (UK)<\/em>
        \nIgG4 related disease – J. Mahajne (Italy)<\/em>
        \nComplement Therapeutics in Autoimmune and Inflammatory Diseases – J. Thurman (USA)<\/em>
        \nHarmonisation of Autoimmune Testing – J. Sheldon (UK)<\/em>
        \nPattern of Thyroid Antibodies in Individuals with Hashimoto\u2019s Thyroiditis and Graves\u2019 Disease in Northern Nigeria – R. Nwaelugo (Nigeria)<\/em>
        \nThe Role of Serum Calprotectin in Defining Disease Outcomes in Non-Systemic Juvenile Idiopathic Arthritis: A Pilot Study – M. R. Flacco (Italy)<\/em>
        \nCredits: 2 CPECS\u00ae<\/strong><\/span><\/li>\n
      • 9:15 – 11:15 AUDITORIUM LA NUVOLA – IFCC SYMPOSIUM<\/span><\/strong>
        \nAdvancing Excellence in Laboratory Medicine Worldwide: An Update from IFCC <\/strong>Taskforces<\/strong> – Session chairs: K. Adeli (Canada), A. Haliassos (Greece)<\/em>
        \nEnhancing Laboratory Quality on a Global Level: Results of the IFCC EQA Pilot Study – E. Amann (Germany)<\/em>
        \nClosing the Gaps in Newborn Screening: The IFCC Global NBS Program – J. Bonham (UK)<\/em>
        \nImpact of the Clinical Laboratory in Clinical Medicine: Developing the Evidence – Z. Zhan (USA)<\/em>
        \nGlobal Database of Adult and Pediatric Reference Intervals – J. Zierk (Germany)<\/em>
        \nCredits: 2 CPECS\u00ae<\/strong><\/span><\/li>\n
      • 9:15 – 11:15 ROOM 5 –\u00a0SIBIOC SYMPOSIUM<\/span><\/strong>
        \nThe challenge of harmonization in laboratory medicine<\/strong> – Session chairs: A. Carobene (Italy), F. Ceriotti (Italy)<\/em>
        \nHarmonization of the Pre-analytical phase – A-M. Simundic (Croatia)<\/em>
        \nHarmonization of the Analytical phase – M. Panteghini (Italy)<\/em>
        \nHarmonization of the Post-analytical phase –M. Plebani (Italy)<\/em>
        \nAnalysis of KDCA Creatinine Standardization program : 5 Years of Experience –\u00a0C.I. Cho (South Korea)<\/em>
        \nComparison Of Sodium Levels In Hyperglycaemic Samples After Applying A Correction Factor – F. De la Fuente (Spain)<\/em>
        \nCredit: 2 CPECS\u00ae<\/strong><\/span><\/li>\n
      • 11:45 – 12:45 AUDITORIUM LA NUVOLA – PLENARY LECTURE <\/strong>– Chair: T. Ozben (Turkey)
        \n<\/em>Viral Evolution and Host Immune Responses<\/strong> – A. Fischer (France)<\/em>
        \nCredit: 1 CPECS\u00ae<\/strong><\/span><\/li>\n
      • 14:30 – 16:30 AUDITORIUM LA NUVOLA – EFLM SYMPOSIUM<\/span><\/strong>
        \nQuality in clinical laboratory: a moving target – <\/strong>Session chairs:\u00a0P. Fernandez-Calle (Spain), D. Vitkus (Lithuania)
        \n<\/em>Evaluation and monitoring of analytical quality – M. Panteghini (Italy)<\/em>
        \nAssessing the robustness of the total testing process with Quality Indicators – V. De Guire (Canada)<\/em>
        \nOutcome measurement and integration of quality measures in laboratory medicine – M. Plebani (Italy)<\/em>
        \nThe CDC Clinical Standardization Programs (CDC CSP) – Improving the Quality of Disease Biomarker Measurements in Patient Care and Research – H. Vesper (USA)<\/em>
        \nImproving Error Reduction In The Post Analytical Phase Of The Laboratory Using Lean 6 Sigma And Benchmarking Tools – M. Mendes (Brazil)<\/em>
        \nCredits: 2 CPECS\u00ae<\/strong><\/span><\/li>\n
      • 14:30 – 15:30 ROOM 6 – PREANALYTICAL CASES<\/strong>
        \nPreanalytical mysteries<\/strong> – S. Jovi\u010di\u0107 (Serbia) – J. Cadamuro (Austria)<\/em>
        \nCredits: 1 CPECS\u00ae<\/strong><\/span><\/li>\n
      • 15:45 – 16:45 ROOM 6 – CLINICAL CASES<\/strong>
        \nBone turnover markers + vitamin D<\/strong> – E. Cavallier (Belgium) – M. Hermann (Germany)<\/em>
        \nThe use of bone turnover markers and vitamin D metabolites for personalized patient management – M. Hermann (Austria)
        \nCredits: 1 CPECS\u00ae<\/strong><\/span><\/li>\n
      • 17:00-18:15 ROOM 5 – 60 YEARS OF CCLM: Talks and Reception<\/strong>
        \n1. Talk by Tomris \u00d6zben – President of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
        \n2. Talk by Khosrow Adeli – President of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
        \n3. Talk by Mario Plebani Editor-in-Chief of Clinical Chemistry and Laboratory Medicine (CCLM)
        \n4. Reception and Social Gathering<\/li>\n<\/ul>\n<\/div>[\/vc_accordion_tab][vc_accordion_tab title=”Day 4″]
        <\/div>

        Wednesday 24 May<\/h2><\/div><\/div>
          \n
        • 9:15 – 11:15 ROOM 1 – SYMPOSIUM 6<\/strong>
          \nPreanalytical phase and patient outcome<\/strong> – Session chairs:\u00a0R. Sierra Amor (Mexico),<\/em> A.M. Simundic (Croatia)<\/em>
          \nHow to measure patient related outcomes & cost of preanalytical errors? \u2013 G. Lippi (Italy)<\/em>
          \nNew venous catheter blood draw device and its impact on patient and laboratory related outcomes \u2013 K. Doyle (USA)<\/em>
          \nOver-estimation of plasma glucose in collection tubes containing citrate stabilizer \u2013 C.M. Florkowski (New Zealand)<\/em>
          \nTransport of clinical samples via Unmanned Aerial Systems like drones does not affect laboratory result\u2019s quality – M. Shapira (Israel)<\/em>
          \nUsing simple algorithm of commonly requested chemistry tests to identify intravenous fluid contamination samples in the clinical laboratory – A. Tsui (Canada)<\/em>
          \nCredits: 2 CPECS\u00ae<\/strong><\/span><\/li>\n
        • 9:15 – 11:15 ROOM 2 – SYMPOSIUM 7<\/strong>
          \nYoung Scientist Session<\/strong> – Session chairs: K. Taha Ucar (Turkey), B. Das (India)<\/em>
          \nCirculating cancer biomarkers: where are we now? – A. Tikhonov (Russia)<\/em>
          \nImmature platelet fraction as an early inflammatory biomarker – C. Imperiali (Spain)<\/em>
          \nDialogue between lab and clinicians for a win-win collaboration \u2013 M. Lenski (France)<\/em>
          \nSetting Reference Intervals for analytes with dynamic physiological changes \u2013 U. Senarathne (Sri Lanka)<\/em>
          \nCredits: 2 CPECS\u00ae<\/strong><\/span><\/li>\n
        • 9:15 – 11:15 ROOM 3 – SYMPOSIUM 8<\/strong>
          \nBone as an endocrine organ<\/strong> – Session chairs: E. Cavalier (Belgium) – A. Haliassos (Greece)<\/em>
          \nFGF23, Lipocalin 2 and Osteocalcin: three hormones released by bone – C. Confavreux (France)<\/em>
          \nSclerostin: from pathophysiology to laboratory determination –\u00a0R. N. J\u00f8rgensen (Denmark)<\/em>
          \nFGF23: clinical and laboratory perspectives – A. Heijboer (Netherlands)<\/em>
          \nBlood Lead Levels In Stunted And Non-Stunted Children In Ibadan, Southwestern Nigeria – O.E. Alo (Nigeria)<\/em>
          \nVitamin D levels status post pandemic: an overview in two sunny regions of Albania – I. Babamusta (Albania)<\/em>
          \nCredits: 2 CPECS\u00ae<\/strong><\/span><\/li>\n
        • 9:15 – 11:15 ROOM 4 – SYMPOSIUM 9<\/strong>
          \nTranslating biomarkers from research to clinical use in traumatic brain injury<\/strong> – Session chairs: A.-C. Chiollaz (Switzerland), K. Makris (Greece)<\/em>
          \nUnderstanding microgl\u00eda-astrocyte communication after traumatic brain injury to study potential new biomarkers – J. Egea <\/em>(Spain)<\/em>
          \nBiomarkers of traumatic brain injury: current state and unresolved issues \u2013 H. Zettenberg (Sweden)<\/em>
          \nNeurovascular Unit-Derived Extracellular Vesicles: From Their Physiopathological Roles to Their Clinical Applications in Traumatic Brain Injury \u2013 A.C. Chiollaz<\/em>\u00a0<\/em>(Switzerland)<\/em>
          \nImplementation of new serum biomarkers of acute brain injury: diagnostic-therapeutic implications in Emergency Department – D. Morell-Garcia (Spain)<\/em>
          \nBiomarkers in patients with mild head trauma under antithrombotic medication – L. Babini (Italy)<\/em>
          \nCredits: 2 CPECS\u00ae<\/strong><\/span><\/li>\n
        • 9:15 – 11:15 AUDITORIUM LA NUVOLA – SIBioC SYMPOSIUM<\/span><\/strong>
          \nThe latest advances in diabetes clinical and laboratory research<\/strong> – Session chairs: A. Mosca (Italy), A. Terreni (Italy)<\/em>
          \nNature of diabetes: time for a rethink? – D. Leslie (UK)<\/em>
          \nDiabetic kidney disease: new clinical and therapeutic issues – G. Pugliese (Italy)<\/em>
          \nRole of glycated albumin for diagnosis and management of diabetes mellitus – E. Selvin (USA)<\/em>
          \nPlacental nutrient transport in gestational diabetes – C. Rodr\u00edguez-Chac\u00f3n (Spain)<\/em>
          \nCan Leptin\/Ghrelin Ratio and Retinol-Binding Protein 4 Predict Improved Insulin Resistance in Patients with Obesity Undergoing Sleeve Gastrectomy? – H. Demerdash (Egypt)<\/em>
          \nCredits: 2 CPECS\u00ae<\/strong><\/span><\/li>\n
        • 11:45 – 12:45 AUDITORIUM LA NUVOLA – PLENARY LECTURE<\/strong>
          \nChair: S. Bernardini (Italy)<\/em>
          \n<\/em>Multi-Omics for Biomarker Discovery: the Value of NMR-Spectroscopy<\/strong> – M. Nauck (Germany)<\/em>
          \nCredit: 1 CPECS\u00ae<\/strong><\/span><\/li>\n
        • 14:30 – 16:30 ROOM 5 – EQALM SYMPOSIUM<\/strong>
          \nInsights into SARS-CoV-2 associated analytics that only EQA schemes can provide <\/strong>\u2013 Session chairs: G.M. Henriksen (Denmark), C. Buchta (Austria)<\/em>
          \nEQA for SARS-CoV-2 antigen detection – Sensitivity of tests and the potential impact of circulating SARS-CoV-2 variants\u00a0\u2013 O. Donoso Mantke (Germany)<\/em>
          \nThree years of external quality assessment for SARS-CoV-2 genome detection in Austria – C. Buchta (Austria)<\/em>
          \nInsights into analytical method performance by combining data from various EQA providers \u2013 Examples from SARS-CoV-2 diagnostics and point-of-care\/near patient testing systems \u2013 W. Coucke (Belgium)<\/em>
          \nResults of SARS-CoV-2 antibody determination – a mess or just biology? \u2013 H. Zeichhardt\u00a0(Germany)<\/em>
          \nCredits: 2 CPECS\u00ae<\/strong><\/span><\/li>\n
        • 14:30 – 15:30 AUDITORIUM LA NUVOLA – CLINICAL CASES<\/strong>
          \nChallenges in the interpretation of laboratory tests in hemostasis<\/strong> – O. Yalcin (Turkey)<\/em>
          \nCredits: 1 CPECS\u00ae<\/strong><\/span><\/li>\n
        • 15:45 – 16:45 AUDITORIUM LA NUVOLA – CLINICAL CASES<\/strong>
          \nNeuroimmune diseases<\/strong> \u2013 Session Chair: J.A. Goodfellow (UK)<\/em>
          \n\u201cBrain on Fire\u201d: Neuroimmunology Case Study Based Discussion \u2013 B. Das (India)<\/em>
          \nTechnical laboratory and clinical challenges and opportunities around autoantibody testing in Neuroimmunology \u2013 J.A. Goodfellow (UK)<\/em>
          \nCredits: 1 CPECS\u00ae<\/strong><\/span><\/li>\n<\/ul>\n<\/div>[\/vc_accordion_tab][vc_accordion_tab title=”Day 5″]
          <\/div>

          Thursday 25 May<\/h2><\/div><\/div>
            \n
          • \n
              \n
            • 9:00 – 11:00 ROOM 1 – SYMPOSIUM 10<\/strong>
              \nBiomarkers of liver diseases – <\/strong>Session Chairs: E. Homsak (Slovenia), D. Pa\u0161ali\u0107 (Croatia)<\/em>
              \nWhat combination of non-invasive fibrosis tests should be used for the diagnosis of fibrosis in NAFLD \/ MAFLD? \u2013 J. Boursier (France)<\/em>
              \nAdipocytokines and liver diseases in 2023: where are we? – C. Peralta (Spain)<\/em>
              \nAre liver-related ANA patterns recognised as a possible hint of liver autoimmune diseases? Brief analysis of patients from a Spanish intermediate complexity hospital\u2019s health area – P. Fern\u00e1ndez Almudena (Spain)<\/em>
              \nDemand Adjustment: alkaline phosphatase and y-glutamiltransferasa. Is it really necessary to request them together? – R.A. Torrado Carri\u00f3n (Spain)<\/em>
              \nCredits: 2 CPECS\u00ae<\/strong><\/span><\/li>\n
            • 9:00 – 11:00 ROOM 2 – SYMPOSIUM 11<\/strong>
              \nThe role of clinical laboratory in kidney transplantation<\/strong> – Session chairs: A. Djamali (USA), T. Trenti (Italy)<\/em>
              \nBiomarkers as non-invasive diagnostic tools in kidney transplantation \u2013 A. Djamali (USA)<\/em>
              \nImmunosuppressive drug Monitoring for a Personalized Therapy \u2013 P. Marquet (France)<\/em>
              \nKidney functions after transplantation: more than glomerular filtration rate \u2013 J. P. Cristol (France)<\/em>
              \nValidation of Enzymatic Creatinine using LCMSMS creatinine measurement, M. Kaplan (Isral)<\/em>
              \nClinical outcome according to eplet mismatches in kidney transplantation recipients without pre-and post-transplant HLA donor-specific antibodies –\u00a0S. Yu (South Korea)<\/em>
              \nCredits: 2 CPECS\u00ae<\/strong><\/span><\/li>\n
            • 9:00 – 11:00 ROOM 3 – SYMPOSIUM 12<\/strong>
              \nSources of interference in laboratory testing<\/strong> – Session chairs:\u00a0G. Dimeski (Australia), S. Jovicic (Serbia)<\/em>
              \nBiotin interference in laboratory testing \u2013 P. B. Kyle (USA)<\/em>
              \nTroponin Interferences with current generation assays \u2013 G. Dimeski (Australia)<\/em>
              \nInterferences in Immunoassays \u2013 K. Ghazal (France)<\/em>
              \nThe role of ascorbic acid in the discordance between esterase and leukocyte cells count in urine samples – D. Morell-Garcia (Spain)<\/em>
              \nIs dilution efficient to eliminate lipemia interferences in biochemistry parameters? –\u00a0I. Mezghani (Tunisia)<\/em>
              \nCredits: 2 CPECS\u00ae<\/strong><\/span><\/li>\n
            • 9:00 – 11:00 ROOM 4 – SYMPOSIUM 13<\/strong>
              \nPrenatal testing<\/strong> – Session chairs:\u00a0B. Das (India),<\/em> G. Novelli (Italy)<\/em>
              \nFirst trimester Fetal Chromosomal Anomaly Screening – G. Novelli (Italy)<\/em>
              \nEQA in prenatal testing and PAPP-A standardisation – C. Sturgeon (UK)<\/em>
              \nRisk assessment for pre-eclamsia throughout pregnancy – L. Poon (Hong Kong)<\/em>
              \nImpact Of Expanded Newborn Screening In The Identification Of Hereditary Diseases In Piedmont And Aosta Valley – P. Sauro<\/em>
              \n(Italy)<\/em>
              \nPilot study for the implementation of newborn screening for spinal muscular atrophy in Southern Spain – R. Yahyaoui (Spain)<\/em>
              \nCredits: 2 CPECS\u00ae<\/strong><\/span><\/li>\n
            • 9:00 – 11:00 ROOM 5 – SIBioC SYMPOSIUM<\/span><\/strong>
              \nDiagnostic workup of monoclonal gammopathies<\/strong> – Session chairs: M. Mussap (Italy) – G. Palladini (Italy)<\/em>
              \nAdvances in monitoring and treatment of multiple myeloma – F. Gay (Italy)<\/em>
              \nDifferential diagnosis of MGCS – A. Dispenzieri (USA)<\/em>
              \nAssessment of CTCs and MRD in multiple myeloma – B. Paiva (Spain)<\/em>
              \nNew lab techniques for management of monoclonal gammopathies – R. Galv\u00e1n (Spain)<\/em>
              \nEvaluating a patient for a monoclonal gammopathy: The \u201cMGTesting\u201d Shiny app – J. Abcede (Australia)<\/em>
              \nCredits: 2 CPECS\u00ae<\/strong><\/span><\/li>\n
            • 11.30 – 12.30 ROOM 1 – PLENARY LECTURE – <\/strong>Chair: R. Horvath (Australia)<\/em>
              \nDiagnostic advances in dementia<\/strong> – K. Blennow (Sweden)<\/em>
              \nCredit: 1 CPECS<\/strong><\/span><\/li>\n
            • 12.30 – 13.30 ROOM 1 – CLOSING CEREMONY<\/strong>Closing remarks<\/strong>
              \nCongress President \u2013 S. Bernardini<\/em>
              \nIFCC President – K. Adeli<\/em>
              \nEFLM President – T. Ozben<\/em>
              \nSIBioC President – T. Trenti<\/em>
              \nWelcome to Dubai<\/strong>
              \nWorldLab Dubai 2024 – T. Ozben, K. Adeli, A. Borai<\/em>
              \nWelcome to Brussels<\/strong>
              \nEuromedlab Brussels 2025 – D. Gruson<\/em>
              \nFarewell Cocktail<\/strong><\/em><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/div>[\/vc_accordion_tab][\/vc_accordion][\/vc_column][\/vc_row][vc_row disable_element=”yes”][vc_column]